United Therapeutics Corporation
UTHRNext catalyst
Inhaled Treprostinil (Tyvaso Nebulizer)
COPD (Chronic Obstructive Pulmonary Disease)
Get an email about UTHR's next catalysts
Track United Therapeutics (UTHR) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (PDUFA date).See the timeline
2 upcoming, 1 past
Inhaled Treprostinil (Tyvaso Nebulizer) Phase 2 Est. Readout
Estimated primary completion for Inhaled Treprostinil (Tyvaso Nebulizer) trial (NCT07037836) in COPD (Chronic Obstructive Pulmonary Disease). Topline data typically follows completion by weeks to months.
SourceFDA PDUFA Date Ralinepag
For Pulmonary Arterial Hypertension. NDA accepted. AI-extracted from: United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Appl
SourceMarket Overview
Stock performance and key metrics
United Therapeutics Corporation is an American biotechnology company that develops pharmaceuticals and technologies related to organ transplantation, including xenotransplantation. Many of the company's products are focused towards lung disease and organ manufacturing. United Therapeutics is co-headquartered in Silver Spring, Maryland and Research Triangle Park, North Carolina, with additional facilities in Magog and Bromont, Quebec; Melbourne and Jacksonville, Florida; Blacksburg, Virginia; and Manchester, New Hampshire.
WebsiteOral treprostinil (UT-15C) Sustained Release Tablets
Pulmonary Hypertension
treprostinil diethanolamine
Pulmonary Arterial Hypertension
Treprostinil Diolamine
Pulmonary Arterial Hypertension
Tadalafil
Pulmonary Hypertension
UT-15
Pulmonary Hypertension
oral treprostinil
PAH
UT-15C SR
Pulmonary Hypertension
Ralinepag
Pulmonary Arterial Hypertension
UT-15C (treprostinil diolamine)
Pulmonary Arterial Hypertension
Dinutuximab
Small Cell Lung Cancer
Inhaled Treprostinil
Progressive Pulmonary Fibrosis
treprostinil dienthanolmine sustained release
Critical Limb Ischemia
Inhaled Treprostinil (Tyvaso Nebulizer)
COPD (Chronic Obstructive Pulmonary Disease)
Universal Donor (UD) TGFΞ²i NK Cells
Neuroblastoma
Hyperpolarized 129Xenon gas
Pulmonary Vascular Disease
Treprostinil
Pulmonary Arterial Hypertension
Qutenza (capsaicin)
Pulmonary Hypertension
Isotretinoin
Neuroblastoma
ch14.18-UTC
Neuroblastoma
Tegaderm
Pulmonary Hypertension
chidamide
HIV-1 Infection
Aldesleukin (IL-2)
Neuroblastoma
Dinutuximab with Chemotherapy
Neuroblastoma
Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
Neuroblastoma
GGTA1 KO Thymokidney
ESRD (End-Stage Renal Disease)
APD811
Pulmonary Arterial Hypertension
ch14.18 -NCI
Neuroblastoma
10 GE Xenokidney
ESRD (End-Stage Renal Disease)
UT-15C
Pulmonary Hypertension
Tyvaso Inhalation Solution
Pulmonary Arterial Hypertension
UB-421
HIV-1 Infection
Ivermectin lotion
Pediculosis Capitis
Irinotecan Hydrochloride
Ganglioneuroblastoma
Qutenza
Pulmonary Hypertension
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Oral treprostinil (UT-15C) Sustained Release Tablets | Phase 3 | Pulmonary Hypertension | - | - |
treprostinil diethanolamine | Phase 3 | Pulmonary Arterial Hypertension | - | - |
Treprostinil Diolamine | Phase 3 | Pulmonary Arterial Hypertension | - | - |
Tadalafil | Phase 3 | Pulmonary Hypertension | - | - |
UT-15 | Phase 3 | Pulmonary Hypertension | - | - |
oral treprostinil | Phase 3 | PAH | - | - |
UT-15C SR | Phase 3 | Pulmonary Hypertension | - | - |
Ralinepag | Phase 3 | Pulmonary Arterial Hypertension | - | - |
UT-15C (treprostinil diolamine) | Phase 3 | Pulmonary Arterial Hypertension | - | - |
Dinutuximab | Phase 3 | Small Cell Lung Cancer | - | - |
Inhaled Treprostinil | Phase 3 | Progressive Pulmonary Fibrosis | - | - |
treprostinil dienthanolmine sustained release | Phase 2 | Critical Limb Ischemia | - | - |
Inhaled Treprostinil (Tyvaso Nebulizer) | Phase 2 | COPD (Chronic Obstructive Pulmonary Disease) | - | - |
Universal Donor (UD) TGFΞ²i NK Cells | Phase 2 | Neuroblastoma | - | - |
Hyperpolarized 129Xenon gas | Phase 2 | Pulmonary Vascular Disease | - | - |
Treprostinil | Phase 2 | Pulmonary Arterial Hypertension | - | - |
Qutenza (capsaicin) | Phase 2 | Pulmonary Hypertension | - | - |
Isotretinoin | Phase 2 | Neuroblastoma | - | - |
ch14.18-UTC | Phase 2 | Neuroblastoma | - | - |
Tegaderm | Phase 2 | Pulmonary Hypertension | - | - |
chidamide | Phase 2 | HIV-1 Infection | - | - |
Aldesleukin (IL-2) | Phase 2 | Neuroblastoma | - | - |
Dinutuximab with Chemotherapy | Phase 2 | Neuroblastoma | - | - |
Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) | Phase 2 | Neuroblastoma | - | - |
GGTA1 KO Thymokidney | Phase 2 | ESRD (End-Stage Renal Disease) | - | - |
APD811 | Phase 2 | Pulmonary Arterial Hypertension | - | - |
ch14.18 -NCI | Phase 2 | Neuroblastoma | - | - |
10 GE Xenokidney | Phase 2 | ESRD (End-Stage Renal Disease) | - | - |
UT-15C | Phase 2 | Pulmonary Hypertension | - | - |
Tyvaso Inhalation Solution | Phase 2 | Pulmonary Arterial Hypertension | - | - |
UB-421 | Phase 2 | HIV-1 Infection | - | - |
Ivermectin lotion | Phase 2 | Pediculosis Capitis | - | - |
Irinotecan Hydrochloride | Phase 2 | Ganglioneuroblastoma | - | - |
Qutenza | Phase 2 | Pulmonary Hypertension | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in United Therapeutics Corporation's drug pipeline?β
CatalystAlert tracks 34 drug candidates in United Therapeutics Corporation's (UTHR) pipeline across Phase 3, Phase 2. Its lead program is Ralinepag (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is United Therapeutics Corporation's next FDA catalyst?β
United Therapeutics Corporation's (UTHR) next tracked catalyst is a Phase 2 readout expected Q3 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track UTHR biotech catalysts?β
Add UTHR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow United Therapeutics Corporation's live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.